Beam-JPM-20240108.pdf

1、PRECISION GENETIC MEDICINES THROUGH BASE EDITINGJANUARY 2024 NASDAQ:BEAMCautionary note regarding forward-looking statementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.Such forward-looking statements include stateme

2、nts regarding:the initiation,timing,progress and results of preclinical studies and research and development programs,including the initiation and progress of clinical trials,including our BEACON trial and our BEAM-201 trial;the advancement of our pipeline,including the advancement of BEAM-101,BEAM-

3、201,BEAM-301,BEAM-302,and additional liver programs in multiple preclinical studies;our current expectations and anticipated results of operations,including our expected use of capital;the sufficiency of our capital resources to fund operating expenses and capital expenditure requirements and the pe

4、riod in which such resources are expected to be available;the potential activities and benefits under license and collaboration agreements and the formation of new collaborations;and the therapeutic applications and potential of our technology,including our potential to develop life-long,curative,pr

5、ecision genetic medicines for patients through base editing,including potential safety advantages,all of which are subject to known and unknown important risks,uncertainties and other factors that may cause our actual results,performance or achievements,market trends,or industry results to differ ma

6、terially from those expressed or implied by such forward-looking statements.Therefore,any statements contained herein that are not statements of historical fact may be forward-looking statements and should be evaluated as such.Without limiting the foregoing,the words anticipate,expect,suggest,plan,v